FOSTER CITY, CA / ACCESSWIRE / October 10, 2016 / Aoxing Pharmaceutical Company, Inc. (NYSE MKT:AXN), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management and addiction treatment pharmaceuticals, today announced that its audited consolidated financial statements for the fiscal year ended June 30, 2016, included in the Company's Annual Report on Form 10-K, which was filed on October 5, 2016 with the Securities and Exchange Commission, contain an audit opinion from its independent registered public accounting firm that includes a going concern qualification.
This announcement is made pursuant to NYSE MKT Company Guide Section 610(b), which requires separate disclosure of receipt of an audit opinion containing a going concern qualification.
CONTACT:
Aoxing Pharmaceutical Company:
646-367-1747
investor.relations@aoxingpharma.com
SOURCE: Aoxing Pharmaceutical Company, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.